Dyne Therapeutics (NASDAQ:DYN) Reaches New 52-Week Low – Here’s What Happened

Dyne Therapeutics, Inc. (NASDAQ:DYN)’s share price hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $13.68 and last traded at $13.72, with a volume of 111192 shares changing hands. The stock had previously closed at $14.11.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on DYN shares. Chardan Capital reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a research note on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research note on Friday, January 10th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $45.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. Robert W. Baird started coverage on shares of Dyne Therapeutics in a research note on Friday, December 13th. They issued an “outperform” rating and a $46.00 price objective for the company. Finally, Baird R W raised shares of Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $49.91.

Dyne Therapeutics Trading Down 0.1 %

The firm has a market capitalization of $1.43 billion, a P/E ratio of -3.96 and a beta of 1.16. The company’s fifty day simple moving average is $24.65 and its 200 day simple moving average is $32.90.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). On average, analysts predict that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Transactions at Dyne Therapeutics

In related news, Director Carlo Incerti sold 16,500 shares of the stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $28.73, for a total transaction of $474,045.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Richard William Scalzo sold 1,455 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total transaction of $40,914.60. Following the sale, the senior vice president now directly owns 127,078 shares in the company, valued at $3,573,433.36. This trade represents a 1.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 21,071 shares of company stock valued at $606,476 in the last three months. 20.77% of the stock is currently owned by company insiders.

Institutional Trading of Dyne Therapeutics

Several institutional investors have recently bought and sold shares of the company. Quantbot Technologies LP purchased a new stake in shares of Dyne Therapeutics during the 3rd quarter valued at about $34,000. Point72 DIFC Ltd bought a new position in shares of Dyne Therapeutics in the 3rd quarter worth approximately $36,000. US Bancorp DE lifted its stake in shares of Dyne Therapeutics by 776.9% in the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after purchasing an additional 1,212 shares during the period. Values First Advisors Inc. bought a new position in shares of Dyne Therapeutics in the 3rd quarter worth approximately $62,000. Finally, KBC Group NV lifted its stake in shares of Dyne Therapeutics by 45.3% in the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after purchasing an additional 978 shares during the period. 96.68% of the stock is owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.